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Abstract
Lysyl oxidase-like 3 (LOXL3) is a member of the lysyl oxidase family comprising multifunctional enzymes with depicted roles in
extracellular matrix maturation, tumorigenesis, and metastasis. In silico expression analyses followed by experimental validation
in a comprehensive cohort of human cell lines revealed a significant upregulation of LOXL3 in human melanoma. We show that
LOXL3 silencing impairs cell proliferation and triggers apoptosis in various melanoma cell lines. Further supporting a pro-
oncogenic role in melanoma, LOXL3 favors tumor growth in vivo and cooperates with oncogenic BRAF in melanocyte
transformation. Upon LOXL3 depletion, melanoma cells display a faulty DNA damage response (DDR), characterized by ATM
checkpoint activation and inefficient ATR activation leading to the accumulation of double-strand breaks (DSBs) and aberrant
mitosis. Consistent with these findings, LOXL3 binds to proteins involved in the maintenance of genome integrity, in particular
BRCA2 and MSH2, whose levels dramatically decrease upon LOXL3 depletion. Moreover, LOXL3 is required for efficient DSB
repair in melanoma cells. Our results reveal an unexpected role for LOXL3 in the control of genome stability and melanoma
progression, exposing its potential as a novel therapeutic target in malignant melanoma, a very aggressive condition yet in need for
more effective treatment options.
Introduction
Lysyl oxidase-like 3 (LOXL3) is a member of the lysyl
oxidase (LOX) protein family that comprises five closely
related members, prototypical LOX and four LOX-like
enzymes (LOXL1–4) [1]. LOX proteins are primarily
known for their role as extracellular enzymes; upon secre-
tion they promote stabilization of collagen and elastin fibers
contributing to extracellular matrix (ECM) maturation [2–
4]. Beyond ECM cross-linking, lysyl oxidases have been
involved in gene transcription, epithelial to mesenchymal
transition (EMT), development, differentiation, and angio-
genesis, as well as in distinct pathologies such as fibrosis
and cancer (reviewed in refs. [5–8]). Some of the emerging
roles of several LOX members are independent of their
secretion and have been associated with their intracellular
and intranuclear localization [5, 6, 8, 9]. Moreover, the
amine oxidase catalytic activity is not always required for
some of the recently reported lysyl oxidase functions,
including their involvement in angiogenesis, EMT, and
inflammation [6, 9–11], suggesting complex and wide-
ranging roles for the members of the LOX family.
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Human LOXL3 presents differential tissue expression
regarding other LOX proteins [12–15] and has been
recently proposed as a candidate gene responsible for
recessive autosomal Stickler syndrome [16], a collageno-
pathy [17], whereas null mutations in LOXL3 have been
associated with early-onset high myopia [18]. Genetic
inactivation in mice has revealed Loxl3 involvement in
skeletal, muscular, and lung development [19–21]. Thus far
the reported roles for LOXL3 were essentially associated
with LOXL3 extracellular activity regarding ECM matura-
tion, whereas LOXL3 involvement in cancer remains lim-
ited. Our previous studies identified human LOXL3 as
modulator of EMT and Snail1 functional activity [22] and
LOXL3 has been involved in the nuclear regulation of Stat3
activity [9]. Since the involvement of several LOX mem-
bers in cancer has been extensively characterized [5, 6, 8],
we explored LOXL3 contribution to human cancer by
interrogating a comprehensive set of human cancer samples
for LOXL3 expression that unveiled an association of
LOXL3 to melanoma. We, therefore, performed gain and
loss-of-function experiments to determine the contribution
of LOXL3 to melanoma pathogenesis. Our studies reveal
that human melanoma cells are addicted to LOXL3
expression since LOXL3 knockdown halts cell proliferation
and triggers apoptosis. Moreover, LOXL3 cooperates to
malignant transformation and contributes to melanoma-
genesis. We have found that LOXL3 binds to proteins that
protect genome integrity (BRCA2, MSH2, SMC1A,
NUMA1) and that its absence promotes a defective DNA
damage checkpoint activation, deficient DNA repair and
aberrant mitosis in melanoma cells. Our data uncover an
unprecedented role for LOXL3 in melanoma biology and
support the relevance of LOXL3 as a novel druggable target
for therapeutic intervention in this severe disease.
Results
LOXL3 is overexpressed in human melanoma
In order to explore the involvement of LOXL3 in cancer, we
performed in silico analyses of public data sets. Mining of the
Cancer Cell Line Encyclopedia (CCLE) database (www.broa
dinstitute.org/ccle) rendered LOXL3 gene expression levels
in 1036 cancer cell lines [23]. Besides Hodgkin lymphoma
and glioma, LOXL3 highest expression was found in mela-
noma and chondrosarcoma (Fig. 1a). Considering LOXL3
mRNA expression levels and the cell lines corresponding to
each tumor type analyzed (n= 61 for melanoma, n= 4 for
chondrosarcoma) [23] we further evaluated LOXL3 role in
melanoma. Data mining of The Cancer Genome Atlas
(TCGA), including whole genome sequencing and tran-
scriptomic profiles of more than 300 cutaneous melanoma
patients [24], revealed upregulated LOXL3 mRNA levels
significantly associated with the presence of well-known
driver mutations in melanoma. In particular, LOXL3 levels
were higher among tumors harboring BRAF activating
mutations whereas a similar trend, without reaching statistical
significance, was observed for the NRAS and the NF1 sub-
type compared to the LOXL3 mRNA levels found in the
triple WT subtype (Fig. 1b). The latter comprised all those
samples not harboring mutations in any of the aforemen-
tioned genes, suggesting a link between canonical MAPK
pathway activation and LOXL3 upregulation in melanoma.
Moreover, examination of published melanoma tran-
scriptomic profiles [25, 26] and TCGA data [24] for LOXL3
expression confirmed a significant upregulation of LOXL3
levels in both primary and metastatic melanoma patient-
derived samples compared to controls (Fig. 1c, d), while no
differences in expression were found between primary and
metastatic samples (Fig. 1c, d; Supplementary Fig. 1a).
Accordingly, analysis of a large cohort of primary and
metastatic melanoma cell lines (Supplementary Table 1)
confirmed increased LOXL3 expression at both LOXL3
mRNA and protein levels in melanoma cells compared to
primary and immortalized human melanocytes (Fig. 1e, f).
As depicted in Fig. 1f, canonical LOXL3 and a splicing
variant lacking exons 4 and 5 (LOXL3ΔE4E5 or LOXL3Δ)
(Supplementary Fig 1b, c), were detected by western blot.
Both LOXL3 isoforms were found similarly expressed in
most melanoma cells tested (Fig. 1f). LOXL3Δ isoform
probably corresponds to the recently identified splice variant
LOXL3-sv2 [27]. LOXL3 expression is thus associated with
both primary and metastatic melanomas, and considerably
upregulated compared to other LOX family members fre-
quently associated with cancer, such as LOX and LOXL2 [5,
6] (Fig. 1f). These results suggest a previously unexplored
role for LOXL3 in melanoma.
Silencing LOXL3 expression in melanoma induces
cell death
To investigate LOXL3 involvement in melanoma, we
initially evaluated the effects of LOXL3 silencing in a panel
of human melanoma cells. We designed two different short
hairpin RNAs (shRNAs) against LOXL3 also targeting
LOXL3Δ without altering LOX and LOXL2 protein levels
(Supplementary Fig. 2a). All melanoma cell lines depleted
for LOXL3 expression halt proliferation between 5–8 days
post-infection (dpi) compared to control cells infected with
a non-targeting control (NTC) (Fig. 2a). LOXL3 depletion
had analogous effects on cells harboring BRAF (A375P,
WM98-1, and SK-MEL-28) or NRAS (SK-MEL-147) acti-
vating mutations as well as on cells wild type for NRAS/
BRAF lacking NF1 protein (MeWo) [28] (Fig. 2a and
Supplementary Table 1). Moreover, LOXL3 silencing was
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Fig. 1 LOXL3 expression levels in human melanoma derived samples. (a)
LOXL3 gene expression levels in human tumor cell lines of the Broad
Institute’s Cancer Cell Line Encyclopedia (CCLE). The number of cell lines
analyzed for each tumor type is annotated. (b) LOXL3 normalized mRNA
levels within the different genomic subtypes for melanoma classification
determined by The Cancer Genome Atlas (TCGA) [24] and defined by
significantly mutated genes in a large sample cohort (n= 356 patients).
Error bars represent s.e.m. ∗p< 0.05 by one-way ANOVA (c) LOXL3
mRNA relative levels from microarray analysis comparing 40 metastatic
melanoma samples, 16 primary melanoma samples, 4 samples of normal
human skin, and 1 sample of human epithelial melanocytes (NHEM). ∗p<
0.05, ∗∗∗p< 0.001 by a Mann–Whitney test. (d) LOXL3 mRNA relative
levels from microarray analysis comparing 76 samples (46 primary mela-
nomas, 14 melanoma metastasis, and 16 normal skin samples). ∗∗∗p<
0.001 by a two-sided Student’s t-test. (e) LOXL3 mRNA expression levels
relative to GAPDH mRNA analyzed by qPCR (8 melanocyte control cell
lines, 14 primary melanomas, and 18 metastatic melanomas, indicated in
Supplementary Table 1). LOXL3 mRNA expression in HMEL (light blue),
501MEL (dark blue), MeWo (light orange), and A375P (red) cells is
indicated. ∗p< 0.05, ∗∗p< 0.01 by a Mann–Whitney test. n.s.: not statis-
tically significant (c–e). (f) LOXL3, LOXL2, and LOX protein levels
analyzed by western blot in primary melanocytes (FM35 and FM32),
immortalized melanocytes (HMEL and PMEL), and human melanoma cell
lines derived from primary or metastatic sites as indicated. LOXL3 and
LOXL3Δ isoforms with different mobility upon western blot analysis are
shown. β-actin was used as a loading control. RGP radial growth phase,
VPG vertical growth phase. Molecular weight (MW) of protein standards
(kDa) is indicated
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deleterious for primary (A375P and WM98-1) and meta-
static melanoma cell lines (SK-MEL-28, SK-MEL-147, and
MeWo) corroborating that melanoma cells require LOXL3
expression to survive independently of their mutational
status or the disease stage from which they were derived.
We then analyzed whether the absence of LOXL3 prevents
Fig. 2 Melanoma cell lines are addicted to LOXL3 expression. (a) Cell
proliferation of human melanoma cell lines transduced with lentiviral
particles expressing control (NTC) and two different LOXL3 targeting
shRNAs (shL3#1 and shL3#2). Cells were infected and then selected
with 1 μg/ml of puromycin for 2 days before cell proliferation was
analyzed; time points in the x-axis indicate days post-infection (dpi).
Representative cell proliferation curves are shown for each cell line
with three experimental replicates for each time point; error bars
represent s.e.m. The experiments were repeated at least three times
with similar results. (b) Downregulation of LOXL3 protein levels was
verified by western blot, as well as the cleavage of caspase-3 (middle
panels), indicative of apoptosis induction, in all the cell lines analyzed.
Cells were infected and selected as in a and attached and floating cells
were collected 4–6 dpi for total protein extraction. α-tubulin was used
as a loading control. LOXL3 and LOXL3Δ isoforms are indicated in
the upper panels. Asterisks (*) indicate a non-specific band recognized
by LOXL3 antibody. MW of protein standards (kDa) is indicated. (c)
Percentage of apoptotic cells in the different melanoma cell lines upon
lentiviral infection with the indicated shRNAs as determined by FACS
analysis of annexin V binding and propidium iodide (PI) uptake. Cells
were infected as in (a) and collected as in (b) before annexin V/PI
incubation. The percentage of annexin V positive and double-positive
cells for both annexin V and PI is indicated. One representative
experiment out of three is shown
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cell growth by triggering apoptosis. Indeed, LOXL3-
depleted cell lines displayed caspase-3 activation (Fig. 2b)
and increased annexin V staining (Fig. 2c) at 5–6 dpi
compared to control NTC-transduced cells. Likewise, effi-
cient LOXL3 silencing by transient siRNA transfection
induced a similar level of apoptosis as shRNA transduction
in SK-MEL-28 cells as shown by caspase-3 cleavage and
annexin V staining (Supplementary Fig. 2b). Moreover, the
CRISPR/Cas9-mediated knockout of LOXL3 in A375P
cells also promoted a cell proliferation delay accompanied
by an increase in apoptotic cell death (Supplementary
Fig. 2c–e). Taken together, we conclude that human mela-
noma cell lines expressing LOXL3 are addicted to the
maintenance of its expression.
LOXL3 promotes tumorigenesis
To assess LOXL3 contribution to melanomagenesis, we
overexpressed LOXL3 in immortalized melanocytes
expressing BRAFV600E (HMEL) [29] with insignificant
levels of endogenous LOXL3 (Fig. 1f and Fig. 3a). This cell
line allows investigating the cooperation of genetic altera-
tions to neoplastic transformation. Stable LOXL3 and
LOXL3Δ expression in HMEL cells greatly enhanced their
anchorage independent growth, a hallmark of transforma-
tion (Fig. 3b) without affecting cell proliferation (Fig. 3c).
Additionally, LOXL3 and LOXL3Δ ectopic expression
favored migration and invasiveness of HMEL cells (Fig. 3d,
e). Similarly, LOXL3 transduction in a metastatic mela-
noma cell line (501MEL) harboring minimal endogenous
LOXL3 levels (Fig. 1f and Supplementary Fig. 3a) pro-
moted migration and invasion without affecting cell pro-
liferation (Supplementary Fig. 3b–d), whereas endogenous
LOXL3 silencing had analogous effects as previously
shown for other melanoma cell lines (Supplementary
Fig. 3e–g). Besides, tumorigenic A375P cells depleted for
LOXL3 (Fig. 2b) showed increased latency and delayed
tumor growth compared to control cells (Fig. 3f). Thus,
enhanced LOXL3 expression cooperates with oncogenic
alterations such as active BRAF to transform human mel-
anocytes favoring migration and invasion of melanoma cells
and supporting melanoma tumorigenicity.
LOXL3 binding partners are involved in mitosis and
the DNA damage response (DDR)
We carried out a comprehensive proteomic analysis of
LOXL3 protein interactors to further understand LOXL3
involvement in melanomagenesis. Since we could not dis-
criminate specific roles for LOXL3 and LOXL3Δ, we ecto-
pically expressed both FLAG-tagged isoforms in metastatic
melanoma 501MEL cell line (Supplementary Fig. 3a) and
performed an anti-FLAG immunopurification followed by
mass spectrometry analysis. After analysis and filtering, we
focused on those common proteins identified in eluates from
LOXL3 and LOXL3Δ transduced cells, falling a number of
them (with 5 to 64 identified peptides) within the functional
categories of mitosis and/or DDR (Fig. 4a and Supplementary
Table 2). To validate the interactions, we performed immu-
noprecipitation experiments in 501MEL and A375P mela-
noma cells expressing ectopic LOXL3 or LOXL3Δ FLAG-
tagged proteins. We detected specific binding of LOXL3 to
BRCA2, SMC1A, MSH2, and NUMA1 (Fig. 4b), proteins
involved in DDR and/or mitosis [30–33], suggesting a role for
LOXL3 in these biological processes. Binding of endogenous
LOXL3 to endogenous BRCA2, NUMA1, and SMC1A
proteins was also confirmed (Fig. 4c and Supplementary
Fig. 4a). LOXL3 localization has been described as cyto-
plasmic/perinuclear [22] and nuclear [9]. Consistent with
LOXL3 binding to recognized nuclear partners, cellular frac-
tionation experiments in A375P cells revealed LOXL3 pre-
sence in the nuclear compartment (Supplementary Fig. 4b).
Further differential centrifugation experiments located LOXL3
and its binding partners in the same enriched cytoplasmic and
nuclear subcellular fractions (Supplementary Fig. 4c) sup-
porting their biological association. Moreover, confocal
microscopy analyses determined LOXL3 and BRCA2 co-
localization in the cytoplasm and perinuclear area of mela-
noma cells (Fig. 4d).
Melanoma cells activate the DDR upon LOXL3
knockdown
The interaction of LOXL3 with proteins involved in
repairing damaged DNA at double-strand breaks (DSBs)
(Fig. 4) led us to hypothesize the association of LOXL3 to
DDR checkpoint activation and/or DSB repair. LOXL3-
silenced A375P cells accumulated phosphorylated H2AX
(γH2AX) foci (Fig. 5a, d, g), a marker of DSBs [34], as well
as 53BP1 foci (Fig. 5b, e), a mediator of DSB repair
(reviewed in ref. [35]) to similar levels to those induced by
known DNA damage agents, such as hydroxyurea or
ionizing radiation (Supplementary Fig. 5a, b). Noticeably, at
early time points post-lentiviral infection (32–56 h pi), and
before any effects on cell proliferation nor apoptosis were
detected (Fig. 2 and Supplementary Fig. 6a), LOXL3-
silenced cells showed activation of ATM (Fig. 5c, f and
Supplementary Fig. 5c), a master checkpoint kinase acti-
vated after DSBs (Supplementary Fig. 5d) and required for
DNA repair and genome stability [36]. Concomitantly,
LOXL3 silencing promoted phosphorylation of the ATM
effector checkpoint substrate, Chk2 (Fig. 5g). In contrast,
activation of ATR, another central kinase mediating DDR
[36], is reduced shortly after LOXL3 knockdown, as levels
of pATR and its immediate target, Chk1, remarkably fell
upon LOXL3 silencing (Fig. 5g). In fact, the levels of other
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relevant downstream effectors of ATM and ATR pathways
that ultimately mediate the repair of DNA damage such as
BRCA1, BRCA2, Rad51, and MSH2 [37, 38], dropped
shortly after LOXL3 depletion (Fig. 5g and Supplementary
Fig. 5e), whereas NUMA1 and SMC1A levels remained
stable (Fig. 5h). p53 and p21 levels increased initially
consistent with DDR activation [36] but p53 levels were not
steadily maintained afterwards (Fig. 5h). Indeed, cells
depleted for LOXL3 displayed reduced ability to repair
DSBs as shown using the DRGFP reporter to measure the
frequency of homologous recombination (HR) [39] (Fig. 5i)
while non-homologous end joining (NHEJ) [40] repair
pathway was not altered (Supplementary Fig. 5f). Alto-
gether, these results suggest that LOXL3 expression in
Fig. 3 LOXL3 contributes to
transformation of immortalized
melanocytes and favors tumor
growth. (a) HMEL immortalized
melanocytes were infected with
GFP lentiviral particles
expressing empty vector (EV),
FLAG-LOXL3, or FLAG-
LOXL3Δ and GFP-positive
sorted cells were analyzed for
the expression of LOXL3
isoforms by western blot. β-actin
was used as a loading control.
MW of protein standards (kDa)
is indicated. (b) Soft-agar colony
formation assay of HMEL
melanocytes transduced as in
(a). Error bars represent s.e.m.,
n= 4 biologically independent
replicates. (c) Cell proliferation
of HMEL melanocytes
transduced as in a. Cell
proliferation is shown for each
cell line with three experimental
replicates; error bars represent s.
e.m. The experiment was
repeated twice with similar
results. (d and e) HMEL
immortalized melanocytes
transduced as in (a) were
analyzed in migration (d) and
invasion (e) assays. Graphs
show the number of migrating
and invading cells quantified
after cell fixation and staining.
Error bars represent s.d., n= 3
biologically independent
experiments. (f) A375P NTC,
shL3#1 and shL3#2 xenografts
were grown in nude mice (n= 8
for NTC, n= 7 for shL3#1 and
n= 6 for shL3#2) and tumor
volume was measured every
week (left). Error bars represent
s.e.m. The percentage of tumors
developed (incidence) in each
group and the required days
from cell injection until the
tumors were measurable
(latency) is shown on the
middle. The average latency and
minimal and maximal days for
latency in each group is also
indicated (right). ∗p< 0.05, ∗∗p
< 0.01, ∗∗∗p< 0.001 by a two-
sided Student’s t-test (b and d–f)
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melanoma cells allows for DNA damage repair by main-
taining the protein levels of BRCA2, Rad51, and MSH2.
Besides, upon LOXL3 silencing, melanoma cells accumu-
late DSBs and subsequently activate the ATM checkpoint
kinase but fail to induce a complete DDR.
LOXL3 is required for proper mitotic completion
We then analyzed the cell-cycle progression of melanoma
cells and unveiled a consistent accumulation of cells in G2/M
phase in the absence of LOXL3 compared to control cells
Fig. 4 LOXL3 physically interacts with proteins involved in genomic
integrity maintenance. (a) Venn diagram showing common proteins
identified by mass spectrometry related to mitosis (green) and DDR
(lilac) in 501MEL cells overexpressing LOXL3 or LOXL3Δ. Proteins
involved in both processes are indicated in the middle (orange letters).
(b) Interaction of selected proteins was confirmed by immunoblot
analyses in A375P and 501MEL cells stably expressing empty vector
(EV), FLAG-tagged LOXL3 (L3) or LOXL3Δ isoform (L3Δ) after
FLAG immunoprecipitation. Whole-cell lysates (WCL) and eluted
samples upon FLAG immunoprecipitation (IP: α-FLAG) were loaded
and western blot analyses with the indicated antibodies were per-
formed. Data are representative of three independent experiments. (c)
Analysis of endogenous protein binding was performed in A375P
whole-cell lysates (WCL) by individual immunoprecipitation (IP) with
specific antibodies against BRCA2, NUMA1, SMC1A, and MSH2.
WCL, control (IP without antibody) and eluates from the indicated
samples were analyzed by western blot for the presence of LOXL3.
MSH2 was not immunoprecipitated. MW of protein standards (kDa) is
indicated (b, c). (d) Confocal images showing co-localization of 55
and 33% (Manders’ Co-localization Coefficient) of LOXL3 and
BRCA2 in A375P and HMEL cells, respectively. Cell lines were
stably transduced with FLAG-LOXL3, fixed and processed for
BRCA2 (green) and FLAG (red) immunofluorescence. DAPI (blue)
was used to stain DNA. White arrows in the merged images mark the
subcellular location where BRCA2 and LOXL3 co-localize. Scale bar:
20 μm
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(Supplementary Fig. 6a). At the molecular level, upon
LOXL3 silencing, MYC levels decreased along with p21 and
p27 upregulation (Fig. 5h), and the protein levels of mitotic
regulators such as AURKA, cyclin A and cyclin B1 were
diminished while CDK1 and cyclin D levels did not sig-
nificantly change compared to control cells (Fig. 5h). Since
LOXL3-depleted melanoma cells ultimately die after shRNA
transduction (Fig. 2), we analyzed how A375P cells were
able to enter and exit mitosis in the absence of LOXL3 at
early time points after infection. G1/S synchronized A375P
control and LOXL3-depleted cells were released into fresh
media to follow their cell-cycle progression by FACS. The
total percentage of A375P cells that entered G2/M phase was
not affected by LOXL3 silencing, whereas a significant delay
in the ability of LOXL3-depleted cells to exit G2/M com-
pared to control NTC cells was detected (Supplementary
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Fig. 6b, c), suggesting an essential role for LOXL3 in G2/M
completion. Correspondingly, we observed that endogenous
LOXL3 protein levels accumulated in cells during G2/M
phase (Supplementary Fig. 6d). To further investigate cell-
cycle progression, LOXL3 shRNAs and scrambled (Ctrl)
shRNA were subcloned into lentiviral vectors expressing
histone 2B-green fluorescent protein (H2B-GFP) or histone
2B-red fluorescent protein (H2B-RFP), respectively [41].
Control (red) and LOXL3 knockdown A375P cells (green)
were synchronized in G1/S, released into fresh media and
their mitotic progression was analyzed by fluorescence time-
lapse imaging from 4 to 48 h. We observed that while 84% of
control cells entered mitosis (122 out of 146, Fig. 6a) taking
approximately 2 h for completion (Fig. 6b), only 49% of
shL3#1 knockdown cells entered mitosis (79 out of 162,
Fig. 6a) and progressed slower (Fig. 6b). Note that even
fewer A375P cells transduced with shL3#2 were able to enter
mitosis (16%, 39 out of 241, Fig. 6a). Particularly, LOXL3-
silenced cells spent more time to progress to anaphase than
control cells (Fig. 6b) and a remarkable fraction of LOXL3-
silenced cells underwent apoptosis before entering mitosis
compared to control cells (Fig. 6c). Moreover, close to 10%
of LOXL3 knockdown cells attempting to divide died
through mitotic catastrophe (Fig. 6f, lower panels, and
Supplementary Fig. 6e). LOXL3-depleted A375P cells also
displayed mitotic abnormalities such as an increased number
of micronuclei (Fig. 6d, f) often related to chromosome
segregation defects [42]. Besides, most of these micronuclei
also accumulated γH2AX (Fig. 5a and Fig. 6e), a marker of
genomic instability. Finally, LOXL3 silencing entailed faulty
chromosome alignment in the metaphase plate and the pre-
sence of lagging chromosomes upon anaphase was also
detected (Fig. 6f, lower panels). The alterations in cell-cycle
progression can be observed in representative videos from
A375P LOXL3-silenced cells compared to control cells
(Supplementary Videos V1-V3). Altogether, these data
indicate that the presence of LOXL3 is required for proper
mitotic progression.
Upregulation of LOXL3 in melanoma contributes to
genomic stability
Due to the aforementioned results involving LOXL3 in
DNA repair mechanisms and mitosis linked to proper
chromosome distribution, we hypothesized that LOXL3
might be required to maintain genome stability of mela-
noma cells. Data mining from the TCGA [24] showed that
upregulated LOXL3 mRNA levels significantly correlate
with a higher presence of copy number alterations (CNA)
and overall mutations in human melanoma samples (n>
300 patients) (Fig. 7a, b). We then performed conventional
comparative genomic hybridization (CGH) profiling of
several primary and metastatic cell lines upon
LOXL3 silencing, identifying many genomic aberrations
associated with the loss of LOXL3 expression (Supple-
mentary Table 3) additionally supporting LOXL3 con-
tribution to genomic integrity in melanoma.
Finally, we explored potential mechanisms responsible for
LOXL3 upregulation in melanoma tumors, in particular
epigenetic control. TCGA data interrogation [24] revealed
that LOXL3 promoter methylation levels (detected with four
independent probes) negatively correlate with LOXL3
mRNA expression in melanoma tumors (Fig. 7c). Remark-
ably, the percentage of methylation of LOXL3 regulatory
regions inversely associates with LOXL3 expression levels in
diverse melanoma cells (Fig. 7d, Fig. 1e and Supplementary
Fig. 7). Moreover, upon inhibition of DNA methylation,
LOXL3 is upregulated in melanoma cells with minimal
endogenous LOXL3 levels (Fig. 7e). These data suggest that
the hypomethylation of LOXL3 promoter in melanoma is one
factor leading to enhanced LOXL3 expression.
Discussion
Recently, accumulating evidence has contributed to recog-
nize the importance of lysyl oxidase family members in a
Fig. 5 LOXL3 is involved in the DNA damage checkpoint. (a–c)
A375P cells were transduced with control (NTC) and LOXL3 tar-
geting (shL3#1 and shL3#2) lentivirus and collected at 56 h pi, fixed
and processed for γH2AX (a), 53BP1 (b), and phospho-ATM (pATM)
(c) immunofluorescence. DAPI (blue) was used to stain DNA.
Representative micrographs are shown. White asterisks a mark the
presence of γH2AX micronuclei. Scale bar: 20 μm. (d-f) Quantitation
of γH2AX (d), 53BP1 (e) and pATM (f) immunofluorescence foci.
Error bars represent s.e.m., n= 5 biologically independent replicates
for γH2AX (1000 total cells analyzed), n= three biological replicates
for 53BP1 (450 total cells analyzed) and n= 2 biological replicates for
pATM (500 total cells analyzed). ∗p< 0.05, ∗∗p< 0.01 by a two-sided
Student’s t-test. (g and h) Whole-protein extracts from control (NTC)
and LOXL3-silenced (shL3#1 and shL3#2) A375P cells after 32 and
56 h pi were subjected to western blot analyses with the indicated
antibodies. AURKA: Aurora Kinase A. α-tubulin (g) and Hsp90 (h)
were used as loading controls. The phospho-ATR (pATR), phospho-
Chk1 (pChk1), and phospho-Chk2 (pChk2) levels were calculated
normalizing to the levels of the corresponding total proteins using
ImageJ and their relative levels regarding NTC control cells are
indicated below the matching immunoblots. Data shown are repre-
sentative of three biologically independent replicates. MW of protein
standards (kDa) is indicated (g, h). (i) HR activity represented as the
percentage of GFP-positive cells analyzed by FACS from A375P
pHPRT-DRGFP cells transduced with control (NTC) and
LOXL3 shRNA lentivirus (shL3#1 and shL3#2) after I-SceI trans-
fection. Error bars represent s.d., n= 4 biologically independent
experiments. ∗p< 0.05 by a two-sided Student’s t-test. Lower panel
displays a scheme summarizing the experiment performed. pHPRT-
DRGFP reporter consists of two defective GFP genes, the first con-
tains an I-SceI endonuclease site. Subsequent cellular expression of I-
SceI leads to a DSB that can be repaired by HR using the downstream
wild-type GFP sequence as a template, resulting in GFP-positive cells
Human melanoma cells are addicted to LOXL3 943
plethora of biological and pathological processes ranging
from ECM maturation to fibrosis, tumorigenesis and
metastasis [5, 6, 8, 43]. LOX proteins have a well-
established role as secreted enzymes contributing to tissue
homeostasis by cross-linking ECM substrates [2, 3].
Nonetheless, the generation of independent loss-of-function
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mouse models of Lox, Loxl1, Loxl2, and Loxl3 genes has
revealed non-redundant roles and distinct contribution to
tissue fitness and proper embryonic development [19–21,
44–46]. In addition to their extracellular roles, recent data
support equally important intracellular functions for some
LOX family members [6–9, 11]. Extensive work by our lab
and others has established the deregulation of lysyl oxidases
in cancer and their status has been associated with patient
outcome in specific neoplasias [5, 6]. Regarding LOXL3,
substantial information reinforces its role in ECM remo-
deling linking deregulated LOXL3 to different connective
tissue disorders [16, 18–21]; however, LOXL3 involvement
in cancer has not been systematically investigated. Our
current in silico analyses in different tumor samples
uncovered a clear association of LOXL3 expression to
melanoma with LOXL3 mRNA being particularly higher
among melanomas carrying well-known oncogenic muta-
tions. LOXL3 expression analyses of an ample set of human
cell lines confirmed both increased mRNA and protein
levels in primary and malignant melanoma samples com-
pared to melanocytes, which were not observed for other
lysyl oxidase members. Interestingly, we found that LOXL3
hypomethylation status is associated with LOXL3 upregu-
lation in melanoma tumor samples and cell lines, supporting
epigenetic regulation as one mechanism contributing to
maintain high LOXL3 expression in this tumor type. Gain
and loss-of-function studies have clarified LOXL3 invol-
vement in melanoma and the consequences of LOXL3
deregulation in primary and metastatic melanoma cell lines.
Importantly, LOXL3 knockdown was found to be deleter-
ious for cell proliferation in melanoma cells independently
of their origin and the oncogenic mutations they harbor.
LOXL3-silenced cells ultimately die through apoptosis and
ectopic LOXL3 expression collaborates with oncogenic
mutations such as BRAFV600E to induce transformation of
immortalized human melanocytes, while forced LOXL3
expression in melanoma cells with minimal endogenous
LOXL3 enhances their migration and invasion capabilities.
Accordingly, tumor growth is delayed in immunocompro-
mised mice orthotopically injected with LOXL3-depleted
melanoma cells corroborating LOXL3 involvement in
melanomagenesis. Mechanistically, we propose that
LOXL3 is responsible for maintaining genome stability
since its depletion promotes DNA damage, partial DNA
damage checkpoint activation and impaired HR activity.
Moreover, LOXL3 silencing leads to a halt in cell pro-
liferation, a delay in cell-cycle progression and defective
mitotic completion. The accumulation of DSBs due to
LOXL3 knockdown activate the DDR through the ATM
pathway, a central player in preventing cells from entering
mitosis with damaged or unreplicated DNA [47]. However,
the ATR pathway is downregulated in LOXL3-depleted
cells, indicating defective activation of the DDR, as
demonstrated by the lower HR activity to repair DSB dis-
played by LOXL3-silenced cells whereas the error-prone
NHEJ repair pathway remained unaffected. Importantly,
LOXL3 specifically interacts with proteins required to
maintain genome integrity (BRCA2, MSH2, NUMA1,
SMC1A), some of which are in turn effectors of the DDR
(BRCA2, MSH2, SMC1A) [36]. Noticeably, some of these
LOXL3 interacting partners are downregulated upon
LOXL3 depletion (BRCA2 and MSH2) as well as BRCA1
and Rad51, also required for DNA repair upon damage.
Similarly, several essential effectors of mitotic entry and
completion like cyclin A, cyclin B1 and AURKA, required
for recovery from DNA damage checkpoint activation [48],
are downregulated upon LOXL3 depletion. Moreover,
LOXL3-silenced cells struggle to reach and complete
mitosis, suffering mitotic catastrophe and apoptosis, or
displaying mitotic abnormalities such as chromosome seg-
regation defects and micronuclei appearance. Additionally,
LOXL3 interacting protein SMC1A is involved in DSBs
repair and is required throughout mitosis to ensure faithful
chromosome segregation [31], whereas NUMA1
Fig. 6 LOXL3 is required for proper mitotic completion. (a) A375P
cells transduced with scramble (Ctrl, H2B-RFP, red) and LOXL3
targeting (shL3#1 and shL3#2, H2B-GFP, green) lentivirus were
synchronized in G1/S with 2.5 mM thymidine for 20 h and upon
release their mitotic progression was followed by high-resolution
fluorescence video microscopy and automated image analysis. The
graph (left) shows the percentage of cells that enter mitosis starting 4 h
after thymidine release and analyzed for 48 h. The total number of cells
that were analyzed in each cell culture and the total number and per-
centage of those cells that enter mitosis is indicated (right). The
experiment was repeated twice with similar results. (b) Graph repre-
senting the length of each mitotic phase measured in the cells recorded
in (a) from control (Crtl) and LOXL3-silenced cells (shL3#1 and
shL3#2) (left). The combined lengths of prophase and metaphase is
significantly longer in cells transduced with shL3#1 and shL3#2
compared to A375P control cells (right). (c) Graph depicting the
percentage of control (Ctrl) and LOXL3-depleted cells (19% of
shL3#1 and 68% of shL3#2) that suffer apoptosis during the 48 h time-
lapse imaging analyzed after thymidine block release. (d) Graph
showing the percentage of control and LOXL3-depleted cells con-
taining micronuclei (n> 100 for control and n> 300 for LOXL3-
silenced cells). (e) Control (Ctrl) and LOXL3-silenced A375P cells
(shL3#1 and shL3#2) were collected at 56 h pi, fixed and processed for
γH2AX immunofluorescence. Graph shows the percentage of γH2AX
positive micronuclei present in these cells (n> 50 for control and n>
250 for LOXL3-silenced cells). Error bars represent s.e.m. (f) Repre-
sentative images from fluorescence time-lapse imaging from control
(red) and LOXL3-depleted A375P cells (green) depicting examples of
regular mitosis (upper panel), lengthier mitosis (middle panel, cell
marked with an arrow), mitotic abnormalities (middle panel, cell
marked by an arrowhead), mitotic catastrophes (lower panel, left, cell
marked by an arrowhead) and lagging chromosomes, resulting in
micronuclei formation (lower panel, right, cell marked by arrows).
Minutes indicating the elapsed time from the start of chromosome
condensation are shown inside phase-contrast images for each indi-
vidual panel. Scale bar: 20 μm. ∗p< 0.05, ∗∗p< 0.01, ∗∗∗p< 0.001 by a
two-sided Student’s t-test (b, d, e)
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coordinates cell-cycle progression and mitotic spindle
function to ensure adequate separation of DNA and cell
division [33]. While NUMA1 and SMC1A protein levels
remain steady upon LOXL3 silencing, we suspect their
function might be compromised in the absence of LOXL3
interacting protein thus contributing to faulty mitosis and
probably further enhancing DNA damage. LOXL2 interacts
with and stabilizes Snail1 by hampering its ubiquitination
[22]. In this line, our results suggest that LOXL3 might
contribute to maintain functional levels of some of its
binding partners such as BRCA2 or MSH2, whereas
LOXL3-mediated regulation of NUMA1 and SMC1A
function remains to be further explored. We also propose
that LOXL3 roles in melanoma are mostly due to the
intracellular protein, based on LOXL3 subcellular locali-
zation and its biologically relevant association to intracel-
lular partners.
Early in tumorigenesis, melanoma cells most likely
escape the DDR checkpoint to enable cell proliferation
despite the accumulation of DNA damage, but later on,
checkpoint-dependent cell-cycle arrest is required to prevent
transformed cells from entering mitotic catastrophe [30, 49].
Melanoma is characterized by a high mutation burden [24],
arising and progressing to malignancy by mechanisms still
poorly understood. Our results support that the presence of
LOXL3 is required for proper DDR and mitosis in mela-
noma cells. Upon LOXL3 silencing, melanoma cells fail to
activate and execute a competent DDR required for cell
survival (illustrated in Fig. 8). Besides, LOXL3 binds to
proteins required for mitosis such as NUMA1 and SMC1A
while LOXL3 depletion prevents proper mitotic comple-
tion. Therefore, we hypothesize that LOXL3 allows mela-
noma cells to survive in the presence of DNA damage since
its depletion results in increased DSBs, genomic aberrations
and defective mitosis leading to cell death. To our knowl-
edge, the present data represent the first report demon-
strating an involvement for LOXL3 in cancer, particularly
establishing melanoma cell addiction to LOXL3, and
uncover a novel association between LOXL3 and
mechanisms of genome integrity maintenance.
Materials and methods
Public data sets analyses
Analyses regarding mRNA expression, tumor mutational
status, sample origin, CNAs, overall number of mutations,
and methylation status were performed at http://www.
cbioportal.org/ on data of skin cutaneous melanoma
(SKCM) patients generated by the TCGA Research Net-
work: http://cancergenome.nih.gov/. LOXL3 accession
number used in the analyses was uc002smp.1. For Riker
et al. [25] and Raskin et al. [26] data sets, the probe of the
array corresponding to LOXL3 was 228253_at.
Cell proliferation and cell synchronization
Melanoma cell lines used in the study were obtained in
2013–2014. Hermes cell were kindly provided by D. Ben-
nett (University of London, London, UK), most SK-MEL
cell lines by A. Houghton (Memorial Sloan-Kettering
Cancer Center, New York, NY), and WM cell lines (as
well as 451Lu) were purchased commercially from the
Wistar Institute (Philadelphia, PA). FM32 and FM35 mel-
anocytes were kindly provided by M. Soengas, (CNIO,
Madrid, Spain) and SB-Cl2 cell line by B. Jiménez (IIB,
Madrid, Spain). A375P, A2058, SK-MEL-2, SK-MEL-5,
SK-MEL-28, 501MEL and MeWo cells were acquired from
ATCC. All experiments were performed within 5–10 pas-
sages after thawing and cells were routinely tested for
mycoplasma contamination. A375P cells were authenticated
by STR profiling. Melanoma cell lines culture and sources
are indicated in Supplementary Data and Supplementary
Table 1. For cell proliferation assays, 2500–5000 cells/well
were seeded in triplicate in 24-well plates, trypsinized and
counted at the indicated time intervals. For each time point,
total cell number was divided by the number of cells at day
1 post-seeding. For G1/S cell synchronization assays,
A375P cells were incubated with 2.5 mM thymidine (Thy,
Sigma-Aldrich) for 20 h (single Thy block) or for 18 h with
2 mM Thy, washed with PBS, recovered in complete media
for 6–8 h and incubated again for 18 h with 2 mM Thy
(double Thy block).
LOXL3 interference and LOXL3 ectopic expression
LOXL3 shRNAs were obtained from the MISSION TRC
shRNA human library (Sigma-Aldrich) in pLKO.1-puro
vector as well as MISSION pLKO.1-puro non-mammalian
shRNA (non-targeting, NTC) control plasmid (SHC002
SIGMA). shRNA scramble control (Crtl) and indicated
LOXL3 shRNAs were subsequently cloned into Histone
H2B-mRFP1 LV-RFP (Addgene 26001) or Histone H2B-
GFP LV-GFP (Addgene 25999), respectively. LOXL3 and
LOXL3Δ (lacking exons 4 and 5) FLAG-tagged cDNAs
were subcloned into pWPI lentiviral vector (Addgene
12254) that allows simultaneous expression of the transgene
and EGFP. Lentiviruses were packaged in HEK293T cells
co-transfecting the lentiviral vector, psPAX2 (Addgene
12260) and pMD2.G (Addgene 12259) with Lipofecta-
mine2000 DNA Transfection Reagent (Invitrogen). Mela-
noma cells were transduced with viral supernatant
supplemented with polybrene (2 μg/mL) and either selected
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Fig. 7 LOXL3 sustains genome stability. (a and, b) ma samples ana-
lyzed by The Cancer Genome Atlas (TCGA) [24] were classified by
CNA (copy number alterations, score) (a) (n= 351 patients) and total
number of mutations (b) (n= 316 patients) and plotted against LOXL3
normalized mRNA levels (first vs. fourth quartile). Error bars represent
s.e.m. ∗p< 0.05 by a two-tailed Student’s t-test. (c) LOXL3 methyla-
tion levels compared to LOXL3 mRNA expression levels in tumors
from the TCGA [24] melanoma data set (n= 473) corresponding to
CpG loci with indicated probes from TCGA [24] within regulatory
regions of human LOXL3 gene. p-value was calculated by two-tailed
Spearman correlation. (d) Percentage of LOXL3 methylation in the
indicated melanoma cell lines (A375P, HMEL, MeWo, and 501MEL)
within the CpG loci corresponding to two probes depicted in c and
three additional probes designed for CpG loci located within intron 1
of human LOXL3 gene (CpG 1–3) (see Supplementary Fig. 7). (e)
501MEL cells were treated with vehicle (DMSO) or 5 µM decitabine
(DAC) and LOXL3 mRNA (left panel) or LOXL3 protein levels (right
panel) were analyzed at the indicated time points, n= 3 biologically
independent replicates. Left, error bars represent s.e.m. ∗∗p< 0.01 by a
two-sided Student’s t-test. Right, results from one representative
experiment are shown. DNMT1 was used to confirm methylation
inhibition by DAC and GAPDH was used as a loading control
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with 1 μg/ml puromycin for 2 days (pLKO based lenti-
viruses) or sorted for EGFP-positive cells using a BD
FACSVantage SE cell sorter (pWPI based lentiviruses). For
LOXL3 transient silencing, 100 nM of LOXL3 ON-
TARGETplus SMARTpool (siSMART-L3) or control
scramble siRNA (Dharmacon) were transfected in mela-
noma cells with Lipofectamine2000 (Invitrogen).
Live-cell imaging analysis
For time-lapse video microscopy, A375P cells expressing
Histone H2B-mRFP1 LV-RFP (Crtl) or H2B-GFP LV-GFP
(shL3#1 or shL3#2) were synchronized in G1/S after
incubation with 2.5 mM thymidine for 20 h and 1.5× 104
cells were seeded on camera chambers (IBIDI). Mitotic
progression was followed by time-lapse microscopy starting
5 h after release in fresh media. Image acquisition was
performed using a Cell Observer (Zeiss) equipped with an
inverted light and fluorescence microscope and built with an
environmental chamber for controlling temperature,
humidity, and CO2. Light and fluorescence images were
acquired with Plan-APOCHROMAT (40x AN1.3) objective
at 5 min intervals and processed using Axiovision Rel.
4.8 software.
Immunoprecipitation and mass spectrometry
analysis
Subsequent to cell lysis, immunoprecipitation of FLAG-
tagged proteins was performed using FLAG-M2 beads
(Sigma-Aldrich) overnight at 4 °C. As a negative control we
used cells transduced with an empty vector to hinder
unspecific binding to FLAG resin. LOXL3 containing
protein complexes were recovered by competitive elution
with 3XFLAG peptide (Sigma-Aldrich) and analyzed by
mass spectrometry. The MS/MS spectra were searched
using the Uniprot human database with LOXL3 and
LOXL3Δ sequences inserted using Sequest within Pro-
teome Discoverer (Thermo Fisher). The data was filtered
using a 1% false discovery rate searched against a decoy
database and only proteins with at least two unique peptides
were retained for further analysis. For immunoprecipitation
of endogenous proteins, cell lysates were incubated with
specific antibodies (Supplementary Table 4) overnight at 4 °
Fig. 8 Working model depicting proposed LOXL3 roles in melanoma.
Melanoma arises through the progressive accumulation of genomic
alterations resulting in uncontrolled tumor cell proliferation followed
by invasion and metastasis. High levels of LOXL3 (a) would sustain
effective DNA repair and activation of cell-cycle checkpoint pathways
allowing melanoma cells to deal with DNA damage. LOXL3 targeting
(b) would hamper the activation of a competent DNA damage
checkpoint leading to a halt in cell proliferation and abnormal mitosis.
The increase in genomic instability due to DSBs and mitotic cata-
strophes would ultimately lead to apoptosis of melanoma cells
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C, followed by precipitation with protein G Dynabeads
(Invitrogen) at 4 °C for 3 h.
Protocols for annexin V staining, cell-cycle analysis, soft
agar, migration, and invasion assays, mouse xenografts,
quantitative real-time PCR (qPCR), western blots, immu-
nofluorescence, subcellular fractionation, CRISPR/Cas9
editing, HR and NHEJ activity, DNA methylation and
array-CGH are described in the Supplementary Data.
A list of antibodies and their use is provided in Sup-
plementary Tables 4 and 5.
Statistical analysis
Statistical significance was performed using GraphPad
Prism 6. Unless otherwise indicated, numerical data are
expressed as mean ± s.e.m. Statistical significance was
determined by two-sided Student’s t-test, one-way
ANOVA, two-tailed Spearman correlation or
Mann–Whitney test. All western blot analyses were inde-
pendently repeated at least three times, and representative
results are shown.
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